See more : Kamat Hotels (India) Limited (KAMATHOTEL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Concert Pharmaceuticals, Inc. (CNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Concert Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aviva plc (AIVAF) Income Statement Analysis – Financial Results
- Red Lake Gold Inc. (RGLD.CN) Income Statement Analysis – Financial Results
- Grand City Properties S.A. (GRNNF) Income Statement Analysis – Financial Results
- Musée Grévin SA (GREV.PA) Income Statement Analysis – Financial Results
- Buffalo Coal Corp. (FBMCF) Income Statement Analysis – Financial Results
Concert Pharmaceuticals, Inc. (CNCE)
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 32.58M | 7.90M | 1.08M | 10.51M | 143.89M | 174.00K | 66.73M | 8.58M | 25.41M | 12.85M | 19.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 87.56M | 61.62M | 59.82M | 43.15M | 30.22M | 36.98M | 28.89M | 27.47M | 21.79M | 24.19M | 23.44M |
| General & Administrative | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.25M | 18.62M | 19.97M | 22.94M | 21.02M | 14.36M | 13.06M | 11.70M | 8.03M | 7.27M | 7.38M |
| Other Expenses | 283.00K | 301.00K | 306.00K | 0.00 | 0.00 | 0.00 | 0.00 | 20.90M | 12.84M | 0.00 | 0.00 |
| Operating Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Cost & Expenses | 110.09M | 80.55M | 80.09M | 66.09M | 51.24M | 51.34M | 41.94M | 39.17M | 29.82M | 31.46M | 30.81M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | -127.00K | 815.00K | 447.00K | 309.00K | 1.15M | 1.67M | 1.86M | 18.00K |
| Depreciation & Amortization | 4.02M | 3.81M | 827.00K | 1.25M | 1.01M | 893.00K | 785.00K | 1.05M | 1.35M | 1.45M | 1.62M |
| EBITDA | -73.49M | -68.84M | -78.19M | -54.46M | 97.16M | -49.83M | 25.70M | -29.50M | -3.04M | -17.14M | -9.68M |
| EBITDA Ratio | -225.57% | -871.15% | -7,259.80% | -518.46% | 67.52% | -28,636.21% | 38.51% | -343.95% | -11.98% | -133.36% | -49.74% |
| Operating Income | -77.51M | -72.65M | -79.02M | -55.58M | 92.65M | -51.17M | 24.79M | -30.60M | -4.41M | -18.61M | -11.35M |
| Operating Income Ratio | -237.92% | -919.35% | -7,336.58% | -529.12% | 64.39% | -29,406.32% | 37.15% | -356.79% | -17.36% | -144.84% | -58.28% |
| Total Other Income/Expenses | -2.54M | -2.20M | 849.00K | -127.00K | 2.69M | 447.00K | -185.00K | -1.10M | -1.65M | -1.83M | 26.00K |
| Income Before Tax | -80.05M | -74.85M | -78.17M | -55.71M | 95.34M | -50.72M | 24.60M | -31.70M | -6.06M | -20.44M | -11.32M |
| Income Before Tax Ratio | -245.72% | -947.24% | -7,257.75% | -530.33% | 66.26% | -29,149.43% | 36.87% | -369.62% | -23.84% | -159.11% | -58.15% |
| Income Tax Expense | 2.54M | -85.00K | -837.00K | 313.00K | -300.00K | 447.00K | 429.00K | 49.00K | 21.00K | 22.00K | 44.00K |
| Net Income | -82.59M | -74.77M | -77.33M | -56.02M | 95.64M | -50.72M | 24.17M | -31.70M | -6.06M | -20.44M | -11.32M |
| Net Income Ratio | -253.53% | -946.17% | -7,180.04% | -533.31% | 66.47% | -29,149.43% | 36.23% | -369.62% | -23.84% | -159.11% | -58.15% |
| EPS | -2.40 | -2.40 | -3.26 | -2.40 | 4.22 | -2.28 | 1.14 | -2.00 | -0.35 | -1.82 | -1.01 |
| EPS Diluted | -2.40 | -2.40 | -3.26 | -2.40 | 4.08 | -2.28 | 1.09 | -2.00 | -0.35 | -1.82 | -1.01 |
| Weighted Avg Shares Out | 34.41M | 31.20M | 23.74M | 23.37M | 22.64M | 22.23M | 21.15M | 15.84M | 17.22M | 11.21M | 11.21M |
| Weighted Avg Shares Out (Dil) | 34.41M | 31.20M | 23.74M | 23.37M | 23.44M | 22.23M | 22.27M | 15.84M | 17.22M | 11.21M | 11.21M |
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by...
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive topline results from its recently completed Phase 3 clinical trial, THRIVE-AA1, evaluating its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that...
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert's THRIVE-AA1 Phase 3 study in alopecia areata meets primary endpoint for scalp hair regrowth and key secondary endpoints at both doses.
What's Going On With CCL Industries Shares Today
RBC Capital analyst Walter Spracklin lowered the price target for CCL Industries Inc (TSX: CCL.B) (OTC: CCDBF) to C$74 from C$80. The analyst maintained the Outperform rating on the shares.
Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2022 Results - Earnings Call Transcript
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Investor Relations Roger Tung - Chief Executive Officer Marc Becker - Chief Financial Officer Nancy Stuart...
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2022. “We are at an exciting point in our progress with CTP-543, our drug candidate for alopecia areata, a serious autoimmune disorder with significant...
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the first quarter of 2022.
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2022. “We are at an exciting point in our progress with CTP-543, our drug candidate for alopecia areata, a serious autoimmune disorder with significant...
Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open. The Company will host a conference call...
Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports